London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
And regarding potential sale of Seed. I have no idea where PBX (LPldl) would stand if this went ahead.
Thanks mol for the summary. Very tricky to est full year revenue. Given confirmed v invoiced in H1. If PBX got between £1.75m-£2m revs full year, I'd be pretty satisfied. But that H1 discrepancy (conf v in) is very big. And as you say, we can expect a jump in admin costs through appt of new staff. All of whom seem to be heads of something so on a generous salary. Though some not in place for full year. But nevertheless, loss could easily increase because of this.
I was referring to the overall financial performance as stated by the BOD - not turnover
and therefore the bottom line - a perhaps even bigger loss
mol
An 83% increase in H1 if repeated in H2 and full year would see 2023 revenue approx £2.3m.
I'd say that was satisfactory. Anything short of £2m would be disappointing imo.
Doesn't depend on my definition at all
mol
It depends on your definition of satisfactory?
What revenue level for the full year 2023 is satisfactory?
Further notes 6 mths June 2023
During the first half of the financial year the Group received confirmed orders totalling £1.5m which is 16% greater than turnover for the period to 31 December 2022 of £1.31m . Of the orders received £552k (2021:£302k) had been completed and invoiced as at 30 June 2023. The 83% increase in sales for the first half of the year reflects strong development in new customer acquisition as well as growth from existing customers.
MInd this in outlook
The Directors and Executives of the Company believe that the financial performance for the first six months of 2023 is satisfactory and reflects the positive momentum the Company has gained as a result of the strategic focus, increased commercial presence, internal competence-building and continued positive science linked to our proprietary
probiotic strain, LPLDL®.
Satisfactory isn't good enough imo
and i'll be astonished if full year results reflect anything other - we have already been warned re increasing overheads in order to take this 44% subsidiary forward!
anyone new here
the BOD
https://probiotixhealth-ir.com/corporate/the-board
mol
Year to 31 dec 2022 £921k received though we don't know seed turnover to then
6 months to June 2023 PBX declared revenue £342,530 US from seed presumably
though I can't remember seeds' reporting period
mol
What would be the Probiotix share on $200m sales?
And its biggest customer
Thanks to Bk2011 for highlighting
June 12 (Reuters) - The owners of Seed Health, one of the few profitable U.S. biotechnology startups, are exploring a sale of the probiotics maker that could value it at more than $1 billion, according to people familiar with the matter.
Seed, which is owned by its founders and co-chief executives Ara Katz and Raja Dhir, as well as venture capital investors, is soliciting acquisition offers with advice from investment bank Centerview, the sources said.
The company expects to generate around $200 million in revenue in 2024, up from about $140 million last year, the sources added, requesting anonymity because the matter is confidential.
Spokespeople for Seed Health and Centerview declined to comment.
Seed is known for its flagship two-in-one DS-01 capsules that support gut, dermatological, cardiovascular and nutritional health. Last month the company launched a vaginal synbiotic, VS-01, to promote the health of the vaginal microbiome.
The microbiome is the collection of microorganisms, like bacteria and viruses, that live in a body or environment.
The Venice, California-based company sells directly to consumers and has both adult and children's supplements. It uses clinical trials to validate its formulas.
Katz and Dhir started the company in 2015 and are the largest shareholders. Investment firm The Craftory led a private financing round in Seed in 2021.
Large consumer health and vitamins companies have snapped up nutritional supplement makers in recent years. Last year, Pharmavite bought women's health company Bonafide, which also has vaginal microbiome-focused products, for $425 million. Also last year, Sanofi acquired vitamins company Qunol for an undisclosed amount.
Formed in 2015 - basically one product - raised a large sum in 2021 (can't remember but think c $60m) and can't remember initial funding but did have a number of high profile investors and whilst a private US company
that's the way to do it!
We have a number of products, rebranded on a number of occasions now, and as FriedmanSowell notes
continue to hide in the shadows after company formed in 2012 and listing in 2014 and of course a disastrous opti wealth destroying, dividend in specie, listing of PBX on aquis
mol
This from Opti re eBay on LinkedIn
https://www.linkedin.com/company/optibiotix-health-plc?trk=organization_guest_main-feed-card_feed-actor-name
I like your thinking Andrew.
Maybe Opti should buy from Amazon as a way of pushing them up the algorithms. They could then resell the same stock from the website.
Boom.
On a slightly less frivolous note, it is a tad frustrating that we have this great product which is hiding in the shadows.
Can’t trade opti on spread but can Pbx, how does that work?
It was indeed tongue in cheek. But too respond to your points
(1) I agree fair point.
(2) Put it in the Garage/ Attic and forget about it. Its a means to an end.
(3) Even at 80p purchase price that's still 25,000 shares therefore an increase in value of 250 quid for every penny Opti share price increases. A 4p increase would cover the initial 1000 pound gummy investment.😀
That's a lot of fibre!!
Andrew67 - I suspect your suggestion was tongue in cheek. But just in case, there are a few teensy problems with it:
1. In terms of Opti's bottom line, you'd be better off buying direct. Rather than via Amazon (where Opti has to pay a hefty commission). Though of course this wouldn't then boost Opti's ranking on Amazon.
2. What on earth's anyone gonna do with a grand's worth of Opti stock?
3. I suspect a lot of private investors on this board are LTHs who bought in at much higher prices than today's. So any share price recovery will boost their coffers far less than you suggest.
Other than that, brilliant idea.
I m guessing that most people on this board hold 20K or more worth of opti shares. At current price this is approximately 120 000 shares. Which means for every 1p increase in price the value increases by £1200.
If everyone on this post bought a grands worth of gummies or shakes or whatever Amazon sells that would contribute to Optis bottom line nicely, thus hopefully pushing the share price up. It would also shoot Opti up Amazon's sales ranking thus leading to better positioning on the site and better sales on Amazon. Again hopefully aiding the share price.
Ordered the gummies from Amazon the other day. Realised after I should probably have done it straight through the company. Will do next time.
Have to say that they are good and effective. Great way of getting fibre in and really did the job of staving off the cravings for sugar I have in the evening.
The upside of buying them from Amazon is I get to post a review on there which hopefully helps.
This time next year Rodney.
Thanks for posting. One day... 🎶
Capital Markets Day 3rd June 2024
Taste Texture Health
https://www.dsm-firmenich.com/content/dam/dsm-firmenich/corporate/documents/results-center/capital-markets-day-2024/capital-markets-day-tth-web-version.pdf
sugar reduction prominent throughout
we continue to live in hope that this year will not become next year as so many have in the past
mol
Whilst we wait audited financial statements
just a bit more recent info re this collaboration which i also believe provides useful info in general for anyone new here
https://www.microbiometimes.com/a-synbiotic-step-forward-dr-lucien-harthoorn-talks-synbiotic-science-and-clasados-collaboration-with-probi/
https://clasado.com/synbiotics-with-bimuno-gos/
albeit clasado ltd is technically insolvent (-£32m) and requires the funding of its owner clasado biosciences ltd a jersey based company - in turn owned by a company in Liechtenstein
Stephen did like to mention Probi - mind don't recall him doing so recently - wouldn't have anything to do with Per, Fred and Steven now at clasado would it?
a pity we didn't have a collaboration with probi prior to a number of ex-opti joining same
suppose though Stephen knows best
we will see (if we haven't already)
bw all
mol
Your Head Groundsman could be a Mensa member and all round genius with superb researching skills😀
没问题
I'm not bad at mowing lawns. But my Mandarin and Cantonese are sadly lacking. 😊